Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 16/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25647154 | 0.92 | CRBN (0.54) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL25646993 | 0.84 | CRBN (0.55) | CRBNDDB1IKZF3GSPT1 | |
| SCHEMBL30459627 | 0.84 | CRBN (0.55) | CRBNDDB1IKZF3GSPT1 | |
| SCHEMBL30460171 | 0.84 | CRBN (0.55) | CRBNDDB1IKZF3GSPT1 | |
| SCHEMBL31076682 | 0.82 | CRBN (0.57) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL25647150 | 0.82 | CRBN (0.57) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL25647213 | 0.82 | DDB1 (0.59) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL23350279 | 0.81 | CRBN (0.61) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL31033571 | 0.81 | CRBN (0.61) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL20046330 | 0.81 | CRBN (0.61) | CRBNDDB1ALDH1A1CHRM2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4446324-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2024-10-16 | — | — | EP | claimed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |